The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

Abstract

This real-world data demonstrate the value of genomic tests in reducing the use of adjuvant chemotherapy in breast cancer. Incorporating clinical characteristics or RSPC scores gives additional prognostic information which may also aid clinicians' decision making.